Welcome to our dedicated page for IDEAYA Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEAYA Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEAYA Biosciences's regulatory disclosures and financial reporting.
IDEAYA Biosciences’ Chief Accounting Officer Andres Ruiz Briseno exercised stock options and sold shares in a pre-planned transaction. On July 7, 2026, he exercised 9,550 stock options at $12.86 per share to acquire common stock, then sold 9,550 common shares in open-market trades at a weighted average price of about $40.01 per share. The sale was executed under his Rule 10b5-1 trading plan adopted on December 19, 2025. Following these transactions, he directly owned 26,466 shares of IDEAYA Biosciences common stock.
IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. As of the April 20, 2026 record date, 87,860,920 common shares were outstanding and entitled to vote.
Stockholders voted on three proposals. For director elections, Yujiro S. Hata received 70,546,418 votes for and 2,470,077 withheld, M. Garret Hampton received 56,718,637 for and 16,297,858 withheld, and Catherine J. Mackey received 70,281,521 for and 2,734,974 withheld, with 10,089,343 broker non-votes for each nominee.
PricewaterhouseCoopers LLP, as independent registered public accounting firm for the year ending December 31, 2026, received 82,579,758 votes for, 141,240 against, and 384,840 abstentions. The non-binding advisory vote on executive compensation received 64,269,756 votes for, 8,349,131 against, 397,608 abstentions, and 10,089,343 broker non-votes.
Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as Lead Independent Director.
IDEAYA Biosciences director Wendy L. Yarno received a grant of stock options for 20,000 shares of common stock at an exercise price of $30.57 per share. The options vest 100% on the earlier of one year from grant or immediately before the next Annual Meeting, subject to continued Board service, and expire on June 16, 2036.
IDEAYA Biosciences director Jeffrey Stein received a grant of stock options to acquire 20,000 shares of common stock at an exercise price of $30.57 per share. These options expire on June 16, 2036 and are intended as equity-based compensation.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant date, provided he continues serving on the board through the vesting date.
IDEAYA Biosciences director Terry J. Rosen received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. According to the footnote, 100% of the option vests on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he continues serving on the Board until that vesting date.
IDEAYA Biosciences director Scott W. Morrison received a grant of stock options for 20,000 shares of Common Stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036. All 20,000 shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if he remains on the Board through that date.
This is a compensation-related award, not an open-market purchase or sale, and leaves him with 20,000 derivative securities reported after the transaction.
IDEAYA Biosciences director Catherine J. Mackey received a stock option grant covering 20,000 shares of Common Stock. The option has an exercise price of $30.57 per share and expires on June 16, 2036. All 20,000 option shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if she continues serving on the Board.
IDEAYA Biosciences, Inc. director Malcolm Garret Hampton received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $30.57 per share and expire on June 16, 2036.
All 20,000 options vest in full on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting following the grant, as long as he continues serving on the board through the vesting date. This filing reflects a compensation-related award rather than an open-market trade.
IDEAYA Biosciences, Inc. completed a sizable equity offering under an underwriting agreement with multiple investment banks. The company sold 7,222,225 shares of common stock, including full exercise of the underwriters’ 1,666,669-share option, and issued pre-funded warrants to purchase 5,555,576 additional shares. The public offering price was $27.00 per share and $26.9999 per pre-funded warrant, with the underwriters purchasing at discounted prices of $25.38 and $25.3799, respectively. IDEAYA reports net proceeds of approximately $323.6 million, after underwriting discounts and estimated expenses, providing substantial new capital for the business. Directors, executive officers and the company agreed to a 60-day lock-up on most share sales, and the securities were issued off an automatically effective shelf registration statement on Form S-3.